Genocea biosciences, inc. (GNCA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

235

221

213

115

121

-

0

0

-

20

224

228

259

Operating expenses:
Research and development

9,987

6,817

6,826

6,849

6,460

6,259

6,359

5,316

7,275

7,880

10,155

11,427

9,742

11,824

8,811

6,678

7,332

6,513

6,058

6,969

8,509

8,654

6,115

4,551

4,407

4,342

3,275

4,098

3,980

General and administrative

3,388

3,045

2,758

3,217

3,017

2,627

4,101

4,472

3,109

2,478

3,750

3,571

3,634

3,858

3,619

4,026

3,924

3,781

3,645

3,172

3,389

2,580

2,843

2,358

1,966

1,848

1,424

879

810

Restructuring Charges

-

-

-

-

-

-

-

-

-

-

2,591

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Refund of research and development expense

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,592

0

0

0

0

-

-

-

-

-

-

-

-

Total operating expenses

13,375

9,862

9,584

10,066

9,477

8,886

10,460

9,788

10,384

10,385

16,496

14,998

13,376

15,682

12,430

10,704

9,664

10,294

9,703

10,141

11,898

11,234

8,958

6,909

6,373

6,190

4,699

4,977

4,790

Loss from operations

-13,375

-9,862

-9,584

-10,066

-9,477

-8,886

-10,460

-9,788

-10,384

-10,385

-16,496

-14,998

-13,376

-15,682

-12,430

-10,704

-9,429

-10,073

-9,490

-10,026

-11,777

-10,926

-8,958

-6,909

-6,373

-6,170

-4,475

-4,749

-4,531

Other income (expense):
Change in fair value of warrants

781

-

2,206

-

-5,787

-

2,894

-

-5,298

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense

-

-

-

-

-

-

-

-

-

-

-

-

0

87

103

111

109

93

39

19

12

-

-

-

-

-

-

-

-

Interest expense, net

259

191

154

299

302

313

266

241

201

346

366

370

359

439

438

430

431

334

320

307

319

-

-

-

-

-

-

-

-

Other income (expense)

0

0

0

0

-1

-2,114

-1

93

-7

358

-6

-7

-359

-

-335

-319

-322

-

-281

-288

-307

-

-

-

-

-

-

-

-

Change in fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

725

56

60

100

6

Loss on debt extinguishment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-200

-

-

Interest expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-213

-237

-231

-120

-104

-108

-127

Total other income (expense)

522

506

2,052

3,571

-6,090

9,236

2,627

5,350

-5,506

-

-372

-377

-

-

-

-

-

-

-

-

-

-724

-213

-237

-956

-176

-364

-208

-133

Net loss

-12,853

-9,356

-7,532

-6,495

-15,567

350

-7,833

-4,438

-15,890

-10,732

-16,868

-15,375

-13,735

-16,034

-12,765

-11,023

-9,751

-10,314

-9,771

-10,314

-12,084

-11,650

-9,171

-7,146

-7,329

-6,346

-4,839

-4,957

-4,664

Unrealized gain on available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

3

-3

-

-9

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized loss on available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-10

-3

-11

0

0

0

180

405

405

400

395

Comprehensive loss

-12,853

-9,356

-7,532

-6,495

-15,567

350

-7,833

-4,438

-15,890

-10,732

-16,868

-15,372

-13,738

-16,042

-12,774

-11,006

-9,751

-10,345

-9,761

-10,311

-12,073

-

-

-

-

-

-4,839

-4,957

-4,664

Unrealized gain on available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-12,853

-9,356

-7,532

-6,495

-15,567

350

-7,833

-4,438

-15,890

-10,732

-16,868

-15,375

-13,735

-16,034

-12,765

-11,023

-9,751

-10,314

-9,771

-10,314

-12,084

-11,650

-9,171

-7,146

-7,329

-6,346

-4,839

-4,957

-4,664

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,650

-9,171

-7,146

-7,509

-6,751

-5,244

-5,357

-5,059

Net loss per share - basic and diluted

-0.46

0.03

-0.28

-0.42

-1.22

-1.33

-0.72

-0.42

-0.22

-0.37

-0.59

-0.54

-0.48

-0.56

-0.45

-0.39

-0.35

639.06

-0.37

-0.43

-640.00

-0.57

-0.53

-0.41

-0.76

-22.55

-17.72

-18.10

-17.09

Weighted-average number of common shares used in computing net loss per share (in shares)

-

27,838

26,681

15,344

12,713

-51,476

10,829

10,693

71,238

28,709

28,666

28,541

28,496

28,398

28,370

28,276

28,152

28,242

26,610

24,154

18,834

17,802

17,465

17,346

9,859

300

296

296

296